The estimated Net Worth of Leslie W.Cavu Management, L... is at least $3.68 millió dollars as of 23 May 2024. Leslie L owns over 30,000 units of Lantern Pharma stock worth over $489,005 and over the last 4 years Leslie sold LTRN stock worth over $3,186,645.
Sign up
Leslie L LTRN stock SEC Form 4 insiders trading
Leslie has made over 6 trades of the Lantern Pharma stock since 2022, according to the Form 4 filled with the SEC. Most recently Leslie sold 30,000 units of LTRN stock worth $189,000 on 23 May 2024.
The largest trade Leslie's ever made was selling 350,000 units of Lantern Pharma stock on 8 November 2022 worth over $1,540,000. On average, Leslie trades about 104,955 units every 90 days since 2020. As of 23 May 2024 Leslie still owns at least 131,453 units of Lantern Pharma stock.
You can see the complete history of Leslie L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Lantern Pharma
Over the last 4 years, insiders at Lantern Pharma have traded over $6,373,290 worth of Lantern Pharma stock and bought 10,000 units worth $150,000 . The most active insiders traders include Aaron G.L.Bios Fund I, Lpbi..., Leslie W.Cavu Management, L... és Maria Luisa Maccecchini. On average, Lantern Pharma executives and independent directors trade stock every 111 days with the average trade being worth of $423,325. The most recent stock trade was executed by Leslie W.Cavu Management, L... on 23 May 2024, trading 30,000 units of LTRN stock currently worth $189,000.
What does Lantern Pharma do?
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.
What does Lantern Pharma's logo look like?
Complete history of Leslie L stock trades at Lantern Pharma
Lantern Pharma executives and stock owners
Lantern Pharma executives and other stock owners filed with the SEC include:
-
Panna Sharma,
Pres, CEO & Director -
David R. Margrave,
CFO & Sec. -
Dr. Kishor Gopaldas Bhatia Ph.D.,
Chief Scientific Officer & Scientific Consultant -
Nicole Leber,
Fin. & Admin. Coordinator -
Dr. Peter L. Nara D.V.M., M.S., Ph.D.,
Co-Founder & Advisor -
Park & Golf Ventures Ii, Ll...,
-
Leslie W.Bios Equity Partne...,
-
David S. Silberstein,
Director -
Leslie W.Bp Directors, Lp B...,
-
Aaron G.L.Bios Fund I, Lpbi...,
-
Park & Golf Ventures Ii, Ll...,
-
Arunkumar Asaithambi,
-
Kishor G. Bhatia,
Chief Scientific Officer -
Franklyn G Prendergast,
Director -
D Jeffrey Keyser,
Director -
Leslie W.Cavu Management, L...,
-
David R. Margrave,
Chief Financial Officer -
Panna Sharma,
President and CEO -
Maria Luisa Maccecchini,
Director